We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Ultrasound Test Detects Ovarian Cancer in Postmenopausal Women with Highest Accuracy Of 96%

By MedImaging International staff writers
Posted on 01 Oct 2024
Print article
Image: The ultrasound test outperformed the current standard of care in the UK significantly in the study (Photo courtesy of 123RF)
Image: The ultrasound test outperformed the current standard of care in the UK significantly in the study (Photo courtesy of 123RF)

Early diagnosis of ovarian cancer is crucial, as the earlier it is detected, the easier it is to treat, leading to more successful outcomes. A new study has now identified an ultrasound test that detected 96% of ovarian cancers in postmenopausal women, potentially offering a more effective alternative to the current standard of care in the UK.

In the high-quality diagnostic test accuracy study, researchers at the University of Birmingham (Birmingham, UK) compared all currently available tests to diagnose ovarian cancer in postmenopausal women head-to-head. Of the six tests evaluated, the IOTA ADNEX model, which examines ultrasound features (the appearance of the lump on the ultrasound), demonstrated the highest accuracy, detecting up to 96% of ovarian cancers. The findings, published in Lancet Oncology, revealed that this ultrasound test significantly outperformed the current standard of care used in the UK.

As a result, the researchers recommended replacing the existing Risk of Malignancy Index (RMI1) test—which detects 83% of ovarian cancers—with the IOTA ADNEX model. The study also highlighted that the model achieved its 96% accuracy when performed by NHS sonographers who received proper training and quality assurance. Since most ultrasounds globally are conducted by sonographers rather than gynecologists, the researchers have developed free online resources to help NHS staff complete the specialized training, obtain certification, and ensure quality assurance for the IOTA ADNEX model.

“This is the first time that a head-to-head study of all available ovarian cancer tests have been done in the same population. Here we studied their use with symptomatic, postmenopausal women who are most at risk of this cancer. Our trial found that the IOTA ADNEX ultrasound protocol had highest sensitivity for detecting ovarian cancer compared to the standard of care and other test,” said Sudha Sundar, Professor of Gynecological Cancer at the University of Birmingham and consultant in gynecological cancer surgery at Sandwell and West Birmingham NHS Trust. “The ultrasound test also performs well when delivered by a trained sonographer who have received specific training and certification and quality assurance, and as the vast majority of ultrasound scans are performed by sonographers it is important that a new standard is able to be delivered by as many clinical professionals as possible.”

Radiology Software
DxWorks
New
MRI Infusion Workstation
BeneFusion MRI Station
Digital Radiographic System
OMNERA 300M
Ultrasound Imaging System
P12 Elite

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.